Targeting the LRRK2 G2019S Mutation Found in Parkinson's Disease: Efficiency of Biosynthesized Solid Lipid Nanoparticles for Therapeutic siRNA-Mediated Gene Therapy

The enhanced therapeutic outcomes observed with the EGB-PLL-SLNPs can be attributed to the bioactive compounds in EGB, particularly the flavonoids and terpenoids, such as quercetin and kaempferol. These molecules play crucial roles in stabilizing mitochondrial membranes, facilitating ATP synthesis, and regulating genes linked to mitochondrial biogenesis. The interaction between EGB and siRNA to mediate gene silencing provides a multifaceted approach to counteracting PD pathophysiology. This study demonstrates that EGB-PLL-SLNPs offer superior gene silencing and cytoprotective effects compared to conventional formulations. The integration of plant-based bioactives with nanomedicine enhances therapeutic delivery and efficacy, positioning biosynthesized PLL-SLNPs as a promising strategy for treating Parkinson's disease.